BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8379339)

  • 1. [Pharmacokinetic studies of epervudine in rats using HPLC].
    Dereszlay I; Mészáros S; Csárdi A; Pátfalusi M; Vereczkey L
    Acta Pharm Hung; 1993 Jul; 63(4):227-36. PubMed ID: 8379339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacokinetic studies of 14C-labeled epervudine in rats].
    Dereszlay I; Vereczkey L
    Acta Pharm Hung; 1993 Jul; 63(4):222-6. PubMed ID: 8379338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic study on a new antiischaemic agent (BRLP-42).
    Csárdi A; Pátfalusi M; Mészáros S; Vereczkey L
    Acta Physiol Hung; 1994; 82(4):321-6. PubMed ID: 7785441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
    Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 2nd communication: drops with ethanol.
    Lintz W; Barth H; Becker R; Frankus E; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 May; 48(5):436-45. PubMed ID: 9638309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical determination and pharmacokinetics of robenacoxib in the dog.
    Jung M; Lees P; Seewald W; King JN
    J Vet Pharmacol Ther; 2009 Feb; 32(1):41-8. PubMed ID: 19161454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioavailability and pharmacokinetic studies of eurycomanone from Eurycoma longifolia.
    Low BS; Ng BH; Choy WP; Yuen KH; Chan KL
    Planta Med; 2005 Sep; 71(9):803-7. PubMed ID: 16206032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitive determination of 20(S)-protopanaxadiol in rat plasma using HPLC-APCI-MS: application of pharmacokinetic study in rats.
    Ren HC; Sun JG; Wang GJ; A JY; Xie HT; Zha WB; Yan B; Sun FZ; Hao HP; Gu SH; Sheng LS; Shao F; Shi J; Zhou F
    J Pharm Biomed Anal; 2008 Dec; 48(5):1476-80. PubMed ID: 19022601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-dependent pharmacokinetics of 1-(2-deoxy-beta-D- ribofuranosyl)-2,4-difluoro-5-iodobenzene: a potential mimic of 5-iodo-2'-deoxyuridine.
    Khalili P; Naimi E; Sun WY; Knaus EE; Wiebe LI
    Biopharm Drug Dispos; 2003 Dec; 24(9):385-95. PubMed ID: 14689467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and bioavailability of 5-ethyl-2'-deoxyuridine and its novel (5R,6R)-5-bromo-6-ethoxy-5,6-dihydro prodrugs in mice.
    Cheraghali AM; Kumar R; Knaus EE; Wiebe LI
    Drug Metab Dispos; 1995 Feb; 23(2):223-6. PubMed ID: 7736915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicokinetics of deltamethrin and its 4'-HO-metabolite in the rat.
    Anadón A; Martinez-Larrañaga MR; Fernandez-Cruz ML; Diaz MJ; Fernandez MC; Martinez MA
    Toxicol Appl Pharmacol; 1996 Nov; 141(1):8-16. PubMed ID: 8917670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic profiles in rats after intravenous, oral, or dermal administration of dapsone.
    Helton DR; Osborne DW; Pierson SK; Buonarati MH; Bethem RA
    Drug Metab Dispos; 2000 Aug; 28(8):925-9. PubMed ID: 10901702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and bioavailability of cefquinome in healthy piglets.
    Li XB; Wu WX; Su D; Wang ZJ; Jiang HY; Shen JZ
    J Vet Pharmacol Ther; 2008 Dec; 31(6):523-7. PubMed ID: 19000274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
    Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Absorption and enterohepatic circulation of baicalin in rats.
    Xing J; Chen X; Zhong D
    Life Sci; 2005 Nov; 78(2):140-6. PubMed ID: 16107266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
    Jagannath K; Chaluvadi MR; Mullangi R; Mamidi NV; Srinivas NR
    Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of CPU0213, a novel endothelin receptor antagonist, after intravenous administration in mice.
    Guan L; Feng Y; Ji M; Dai DZ
    Acta Pharmacol Sin; 2006 Mar; 27(3):367-71. PubMed ID: 16490175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
    Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
    Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model.
    Sobol E; Bialer M
    Biopharm Drug Dispos; 2004 May; 25(4):157-62. PubMed ID: 15108218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonlinear oral pharmacokinetics of the alpha-antagonist 4-amino-5-(4-fluorophenyl)-6,7-dimethoxy-2-[4-(morpholinocarbonyl)-perhydro-1,4-diazepin-1-yl]quinoline in humans: use of preclinical data to rationalize clinical observations.
    Harrison A; Betts A; Fenner K; Beaumont K; Edgington A; Roffey S; Davis J; Comby P; Morgan P
    Drug Metab Dispos; 2004 Feb; 32(2):197-204. PubMed ID: 14744941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.